In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Class 1 Obesity. BMI range: 30 to 34.9 Class 1 obesity is the first stage of obesity and, while the mildest, it still raises the risk of health problems—especially if weight keeps increasing.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Overall, we believe RT-114 has the potential to fill the current gap in the obesity treatment landscape as a first-in-class oral bispecific GLP-1/GLP-2 receptor agonist. Our Phase 1 study of RT ...

0.5 percent with obesity were prescribed an obesity medication in 2023; ... (aPR, 2.24), and among those with class 2 or 3 vs class 1 obesity (aPRs, 4.03 and 12.78, respectively).

Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like peptide-1 agonists) that have upended the treatment of obesity in recent years, offering hope to patients who have ...